Public notice & comment
After careful consideration of all applications submitted to WHO, the following individuals are proposed for membership of the WHO Advisory Committee on the Safety of Medicinal Products (ACSoMP).
Following a public call for experts, the World Health Organization (WHO) today announced proposed members of the WHO Advisory Committee on the Safety of Medicinal Products (ACSoMP). ACSoMP provide advice to the World Health Organization Director-General on pharmacovigilance policy and issues related to the safety and effectiveness of medicinal products.
The 15 proposed ACSoMP members have expertise in a range of areas including, but not limited to the following:
- Pharmacovigilance
- Public health programmes (e.g., HIV, TB, Malaria)
- Statistics and/or pharmacoepidemiology
- Pharmacy/ clinical pharmacology
- Drug regulation
- Ethics/ research in drug safety and/or academia
- Medication errors and patient safety
- Health systems strengthening
- National and international pharmaceutical policy
- Maternal health/paediatrics
The composition of the ACSoMP reflects geographic and gender diversity as much as possible in accordance with interest expressed.
As per WHO processes, there will now be a two-week public consultation period for WHO to receive feedback on the proposed ACSoMP members and set in place the modalities for the next ACSoMP meeting, which is planned to take place following this consultation period. The final membership to the ACSoMP is subject to the above-mentioned public consultation period and relevant WHO practices and procedures.
Proposed ACSoMP members
- Dr Hussain Al Ramimmy: Pharmacovigilance and Drug Information, Oman
- Dr Angela Caro-Rojas: International Society of Pharmacovigilance, Colombia
- Dr Gerald Dal Pan: US Food and Drug Administration (FDA), United States of America
- Dr Jean-Christophe Delumeau: Institute of Pharmacovigilance: Coquitlam, Canada
- Dr Gloria Giraldo: Health Canada, Canada
- Dr Richard Hill: Therapeutic Goods Administration, Australia
- Dr Viola Macolic Sarinic: European Medicines Agency (EMA), Scientific lead of the Pharmacovigilance risk assessment committee (PRAC), The Netherlands
- Dr Ushma Mehta: University of Cape Town, Co-OI UBOMI BUHLE Pregnancy Exposure Registry, South Africa
- Dr Lembit Rägo: Council for International Organizations of Medical Sciences (CIOMS), Switzerland
- Professor Maria Teresa Herdeiro: Aveiro University Portugal
- Dr Mulugeta Russom: Eritrean Pharmacovigilance Centre, Eritrea
- Dr Hadir Rostom: Pharmacovigilance consultant, Egypt
- Dr Sabin Straus: Medicines Evaluation Board, The Netherlands
- Professor Michael Tatley: University of Otago, New Zealand
- Dr Marco Tuccori: University Hospital of Pisa, Italy
Pursuant to WHO’s rules and practices, and in order to enhance WHO’s management of conflicts of interest, as well as strengthen public trust and transparency in connection with WHO advisory groups involving the provision of technical advice, the names and brief biographies of the individuals selected for ACSoMP Membership are now disclosed for public notice and comment.
Should you wish to comment on the individuals, please send your comments to pvsupport@who.int with subject, “Public comments on ACSoMP members,” by Monday 8 April, 17:00 CET.
Disclaimer:
WHO will treat the comments received through this public notice and comment process confidentially. Comments and perceptions brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment policy and will, subject to WHO’s rules, practices, and policies, be carefully reviewed by WHO. WHO reserves the right to discuss information received through this process with the relevant expert and otherwise within the Organization as appropriate, with no attribution to the provider of the information. WHO, may, in its sole discretion, take appropriate action in accordance with its rules, practices, and policies, based on any information received.